Furthermore, we observed that systemic levels of IL-8 and IL-10 differed according to the tumor grade, with higher levels in patients with glioblastoma (WHO grade IV) compared to lower grade glioma (WHO grade II–III). This evidence concerns the gene IL10 and central nervous system cancer.